Abstract
BackgroundAs biosimilars are approved and commercialised for rheumatic diseases, patients may be switched from originator biologic treatment to biosimilars due to perceived cost savings between the two biologic products. However,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
